|Chemical and physical data|
|Molar mass||146.5 kg/mol g·mol−1|
|(what is this?)|
Girentuximab (trade name Rencarex) is a chimeric IgG1 monoclonal antibody to carbonic anhydrase IX (CAIX). CAIX is expressed on the surface of most renal cancer cells and is hypothesized to be on the surface of other tumor cells. It is investigational agent in clinical trials for renal cell carcinoma. Its development was suspended as a "naked" or unconjugated antibody during phase III trials due to efficacy.
Girentuximab was originally developed by Wilex AG. It was granted fast track status and orphan drug designation by the FDA for renal cancer. In January 2017, Telix Pharmaceuticals Limited, an Australian biotechnology company, announced that it had in-licensed Girentuximab for use as a radioimmunoconjugate.
- "Statement On A Nonproprietary Name Adopted By The USAN Council: Girentuximab" (PDF). American Medical Association.
- Bedke J, Stenzl A (2013). "Immunotherapeutic strategies for the treatment of renal cell carcinoma: where are we now?". Expert Review of Anticancer Therapy. 13 (12): 1399–408. doi:10.1586/14737140.2013.856761. PMID 24215158.
- "WILEX signs antibody license agreement with Telix Pharmaceuticals Limited | WILEX AG". www.wilex.de (in German). Retrieved 2017-09-18.
- Girentuximab (Rencarex) for renal cell carcinoma
|This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it.|
|This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.|